Methotrexate Pfizer (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate, a cofactor required for synthesizing DNA, RNA, and proteins. This inhibition limits the growth of rapidly dividing cells, such as immune cells in autoimmune disease and cancer cells in hematologic malignancies.

The specific dose and schedule of Methotrexate Pfizer are determined by the prescribing clinician based on the indication, patient weight, renal function, and treatment goals. Healthcare providers tailor the regimen to achieve therapeutic benefit while minimizing toxicity.

Methotrexate is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended during breastfeeding because it can be excreted in milk and harm the infant.

To request Methotrexate Pfizer, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Methotrexate shares a similar mechanism with other folate antagonists such as pemetrexed, but it is distinguished by its broader range of approved indications, including autoimmune diseases and several cancers. Its dosing flexibility and extensive clinical experience make it a first‑line option in many treatment protocols.

Methotrexate Pfizer should be stored at ambient temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Methotrexate Pfizer is supplied as a sterile injectable solution and can be given via intra‑arterial, intramuscular, or intravenous routes, depending on the clinical indication and physician preference. Administration is performed by qualified healthcare professionals in a controlled setting.

The most serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to infection or bleeding, renal failure, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for early signs of these complications.

Methotrexate Pfizer is contraindicated in pregnant women, individuals with severe liver disease, uncontrolled infections, and those with known hypersensitivity to methotrexate or its excipients. Caution is also advised for patients with impaired renal function or existing blood‑cell disorders.